After partnering with LIVI and launching the Reboot Quiz, Boots UK has announced that it is piloting the Doctor Care Anywhere (DCA) ePrescription service in 20 stores across central London.
Its introduction means that patients will be able to have their prescriptions sent electronically to a Boots pharmacy “within moments” of their consultation.
DCA, which is registered with the Care Quality...
Alto, a digital pharmacy and drug delivery company, will announce next week the close of a $250 million Series D funding round headed by SoftBank’s Vision Fund 2, Reuters and others reported this morning. Greenoaks Capital, Jackson Square Ventures and other prior backers also participated in the round.
This round would bring Alto’s total raise to more than $350 million, and its valuation to more...
Update: HIMSS20 has been canceled due to the coronavirus. Read more here.
While many would agree that healthcare is turning a corner with increasing focus on patient-friendly experiences and the consumerization of healthcare services, not every attempt in this area has been a home run. These shortcomings have been particularly disappointing in the realm of digital, where a successful, well-...
San Francisco-based EHR developer Practice Fusion has agreed to pay $145 million alongside an admission that it “solicited and received kickbacks from a major opioid company” in exchange for clinical decision support (CDS) alerts promoting unnecessary prescription opioids, according to a release from the US Department of Justice.
In a settlement announced yesterday (and hinted at in an earnings...
Unfortunately for us, MobiHealthNews doesn’t have a crystal ball (it would be darn useful for getting scoops). But we do have more than a decade’s worth of experience tracking the emergence of this space and we spend a lot of our time talking to smart people with industry experience and opinions of their own.
As we enter into a new decade in 2020, your MobiHealthNews staff has put our heads...
Update: HIMSS20 has been canceled due to the coronavirus. Read more here.
About the author: Naomi Fried, PhD, is the CEO of Health Innovation Strategies, which provides digital health strategy and innovation-program design and optimization consulting to healthcare stakeholders including pharma, payers and providers. Her previous positions include the first chief innovation officer at Boston...
Editor's note: This story has been updated with information from Verily's announcement of the clearance.
Verily, the life sciences research subsidiary of Alphabet, has received FDA 510(k) clearance for an augmented version of its prescription Study Watch wearable that includes some form of arrhythmia monitoring.
The Study Watch With Irregular Pulse Monitor is classified by the FDA as a “...
Following news of hardships at Proteus Digital Health, CEO Andrew Thompson has told STAT News that the company is winding down its high-profile $88 million deal with Otsuka Pharmaceutical, and will be pivoting from its current primary focus on mental disorders toward cancers and infectious disease treatments.
The pharmaceutical company has now acquired the full license for Proteus’ mental health...
German pharma giant Bayer and British biotech firm Exscientia have announced a three-year partnership focused on the use of Artificial Intelligence in cardiovascular and oncology drug discovery.
The collaboration will initially see the companies work on three early-stage research projects, combining Bayer’s data and drug discovery capabilities and Exscientia’s Centaur Chemist platform.
According...
Editor's note: This story has been updated with additional statements from Pear Therapeutics.
Pear Therapeutics pulled back the curtain this morning on a number of new deals between the prescription digital therapeutics maker and other tech companies or researchers.
Ranging from virtual reality therapies to voice biomarker tech, the moves appear to be an effort from Pear to add new products to...
